Sichuan Jiuzhang Biotechnology Co., Ltd., established on 1999-04-27, Business scope includes drug research and development;chemical reagent(Free of Hazardous Chemicals)Research,Sales;Polymer Materials,biomaterials(Except for those prohibited by national laws and regulations and with special provisions)Research,Production,Sales;Sales:Chemical Products(Free of Hazardous Chemicals);Import and export,Technology Import and Export(National law,Except where prohibited by administrative regulations;law,Projects restricted by administrative regulations can only be operated after obtaining a license;The industrial industry involved in production establishes another branch or chooses another business site for operation);Sales of Jiuzhang Lutai Chewable Tablets(Operate within the validity period with the license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

Vanquish Oncology is a biotechnology company that develops targeted, small-molecule oncology therapeutics for unmet or underserved cancer markets. It features an advanced program in selectively triggering cancer cell death through activating procaspase 3, a key late-stage effector of apoptosis. The company was founded in 2011 and headquartered in Champaign, Illinois.

The Texas A&M University System creates a seamless pathway for students to earn an associate and bachelor’s degree in related fields

CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Hospices Civils de Lyon provides health care services. It operates facilities including various predominantly general facilities that offers emergency, medical and surgical services in a wide range of disciplines, specialist facilities and four geriatric facilities. The company is headquartered in Lyon, France.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Hangzhou Buping Medical Laboratory Co., Ltd., established on 2020-10-27, Business scope includes licensed projects:medical service;Inspection and testing service;Production of Class II Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Import and export;Technology Import and Export;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development;Health Consulting Services(Does not include medical services);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Wholesale of computer software, hardware and auxiliary equipment;Retailing of computer software, hardware and auxiliary equipment;Instrument sales;Chemical product sales(No licensed chemical products);Production of Class I Medical Devices;Specialty Chemicals Sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.